Feature | June 14, 2012

FDA Panel Recommends Expanding Sapien Transcatheter Valve for High-Risk Patients

Expanded indication would make TAVR more widely available

June 14, 2012 — A U.S. Food and Drug Administration (FDA) advisory panel voted in favor of recommending expanding the indication for the Edwards Lifesciences Sapien transcatheter heart valve for the treatment of high-risk patients. Currently, the Sapien is only indicated for patients who are too sick to undergo valve replacement surgery for severe, symptomatic aortic stenosis. The panel voted 11-0, with one abstention, that the benefits of the heart valve outweighed the risks for these patients.

If the FDA clears the additional indication, it will further expand the use of transcatheter aortic valve replacement (TAVR) therapy to more patients. Many experts predict TAVR will eventually replace the very invasive gold-standard therapy of open-heart aortic valve replacement surgery in the coming years.

Edwards submitted a premarket application (PMA) in April 2011 based on data from the high-risk cohort (Cohort A) of the PARTNER trial. Cohort A compared the outcomes of patients at high risk for traditional open-heart surgery, evenly randomized to receive either surgical aortic valve replacement or the Sapien valve via transfemoral or transapical delivery. In November 2011, the FDA approved the Sapien valve via transfemoral delivery for the treatment of inoperable patients with severe, symptomatic aortic stenosis.

"We are very encouraged by the advisory panel's strong recommendation for approval to expand the current indication for the Edwards Sapien valve to patients at high risk for surgery. A broader indication for high-risk patients would enable multi-disciplinary heart teams to choose the approach best suited to their patients' needs, including for the first time a transapical delivery option," said Michael A. Mussallem, Edwards' chairman and CEO. "We look forward to working closely with the FDA during the review process, and thank the panel for their thoughtful analysis of the PARTNER trial results."

The Sapien valve is currently an investigational device for the treatment of high-risk operable patients in the United States.

For more information: www.edwards.com

Related Content

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology| January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology| January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology| November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology| November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology| November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Videos | Heart Valve Technology| November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Harpoon Mitral Valve Repair System data reported at TCT 2017
Feature | Heart Valve Technology| November 07, 2017
November 7, 2017 – A new study has found that a pioneering device to repair heart valves is safe and effective, and c
Videos | Heart Valve Technology| November 07, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, explains the current state o
Overlay Init